154 related articles for article (PubMed ID: 32745642)
1. Somatostatin Receptor-Targeted Radioligand Therapy in Head and Neck Paraganglioma.
Roll W; Müther M; Sporns PB; Zinnhardt B; Suero Molina E; Seifert R; Schäfers M; Weckesser M; Stegger L; Beule AG; Stummer W; Rahbar K
World Neurosurg; 2020 Nov; 143():e391-e399. PubMed ID: 32745642
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.
Gubbi S; Al-Jundi M; Del Rivero J; Jha A; Knue M; Zou J; Turkbey B; Carrasquillo JA; Lin E; Pacak K; Klubo-Gwiezdzinska J; Lin FI
Front Endocrinol (Lausanne); 2020; 11():587065. PubMed ID: 33551992
[TBL] [Abstract][Full Text] [Related]
3.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas.
Schmidt M; Fischer E; Dietlein M; Michel O; Weber K; Moka D; Stennert E; Schicha H
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1571-80. PubMed ID: 12458390
[TBL] [Abstract][Full Text] [Related]
5. Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours).
Puranik AD; Kulkarni HR; Singh A; Baum RP
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1223-30. PubMed ID: 25822655
[TBL] [Abstract][Full Text] [Related]
6. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).
Zovato S; Kumanova A; Demattè S; Sansovini M; Bodei L; Di Sarra D; Casagranda E; Severi S; Ambrosetti A; Schiavi F; Opocher G; Paganelli G
Horm Metab Res; 2012 May; 44(5):411-4. PubMed ID: 22566197
[TBL] [Abstract][Full Text] [Related]
7. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
Müther M; Roll W; Brokinkel B; Zinnhardt B; Sporns PB; Seifert R; Schäfers M; Weckesser M; Stegger L; Stummer W; Rahbar K
Nuklearmedizin; 2020 Sep; 59(5):348-355. PubMed ID: 32691404
[TBL] [Abstract][Full Text] [Related]
8. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
Severi S; Bongiovanni A; Ferrara M; Nicolini S; Di Mauro F; Sansovini M; Lolli I; Tardelli E; Cittanti C; Di Iorio V; Mezzenga E; Scarpi E; Ibrahim T; Paganelli G; Zovato S
ESMO Open; 2021 Aug; 6(4):100171. PubMed ID: 34139487
[TBL] [Abstract][Full Text] [Related]
9. Peptide receptor radionuclide therapy in head and neck paragangliomas – Report of 14 cases.
Estêvão R; Duarte H; Lopes F; Fernandes J; Monteiro E
Rev Laryngol Otol Rhinol (Bord); 2015; 136(4):155-8. PubMed ID: 29400037
[TBL] [Abstract][Full Text] [Related]
10. Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With
Huot Daneault A; Desaulniers M; Beauregard JM; Beaulieu A; Arsenault F; April G; Turcotte É; Buteau FA
Front Endocrinol (Lausanne); 2021; 12():705271. PubMed ID: 34367072
[TBL] [Abstract][Full Text] [Related]
11. Complete Response to 177 Lu-DOTATATE PRRT in a 9-Year-Old Child With Metastatic Carotid Body Paraganglioma.
Yadav MP; Raju S; Ballal S; Bal C
Clin Nucl Med; 2024 Jan; 49(1):e33-e34. PubMed ID: 37976428
[TBL] [Abstract][Full Text] [Related]
12. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
13. Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.
Thiis-Evensen E; Poole AC; Nguyen HT; Sponheim J
BMC Cancer; 2020 May; 20(1):466. PubMed ID: 32448245
[TBL] [Abstract][Full Text] [Related]
14.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
15. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
16. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of
Medaer E; Verslype C; Van Cutsem E; Dekervel J; Clement PM; Nackaerts K; Laenen A; Gheysens O; Goffin K; Jentjens S; Van Laere K; Deroose CM
Acta Oncol; 2020 Jun; 59(6):644-651. PubMed ID: 32036716
[No Abstract] [Full Text] [Related]
17. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
18. 177Lu-DOTATATE PRRT in Recurrent Skull-Base Phosphaturic Mesenchymal Tumor Causing Osteomalacia: A Potential Application of PRRT Beyond Neuroendocrine Tumors.
Basu S; Fargose P
J Nucl Med Technol; 2016 Dec; 44(4):248-250. PubMed ID: 27634982
[TBL] [Abstract][Full Text] [Related]
19. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
[TBL] [Abstract][Full Text] [Related]
20. Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy.
Gabriel M; Nilica B; Kaiser B; Virgolini IJ
J Nucl Med; 2019 Apr; 60(4):524-529. PubMed ID: 30115690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
